FUNDAMENTALS · Fundamentals · US Healthcare

CVRx (CVRX) Fundamentals 2026 — Revenue Analysis | SniperIQ

CVRx (CVRX) is a US-listed Healthcare company in Medical - Devices with a market capitalization of

35M, trading at $5.07 on the NASDAQ. This SniperIQ fundamentals page covers CVRx's valuation, profitability (net margin -89.1%), revenue ($57M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
35M
Net Margin-89.1%
Revenue (FY25)$57M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is CVRx's market cap?

CVRx (CVRX) has a market capitalization of approximately

35M, trading at $5.07 on the NASDAQ. Market cap moves with the live share price.

What is CVRx's P/E ratio?

CVRx's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CVRx?

CVRx runs a net profit margin of -89.1%, a gross margin of 85.5%, and an operating margin of -84.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CVRx generate?

CVRx reported revenue of $57M for fiscal year 2025, with net income of -$53M and earnings per share (EPS) of -2.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CVRx pay a dividend?

CVRx does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is CVRx financially healthy?

CVRx carries a debt-to-equity ratio of 2.04x and a current ratio of 10.20x, with a market beta of 0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CVRx a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CVRx (CVRX) the key facts are: market cap

35M, revenue $57M, 52-week range 4.37-11.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track CVRx's full fundamentals live

Get CVRx's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Aardvark Therapeutics, Inc. Common Stock (AARD) fundamentals · AN2 Therapeutics (ANTX) fundamentals · Adagene (ADAG) fundamentals · Acumen Pharmaceuticals (ABOS) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons